Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NASH Contender Inventiva Backed By Euronext IPO

Executive Summary

The five-year-old French biotech Inventiva Pharma has raised financing on the public markets to propel its lead fibrosis/NASH product through the development pipeline.

You may also be interested in...



NASH Companies Take The Stage At AASLD

NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.

Cirius Suspects Insulin Resistance Is Underlying Key To NASH

The former Octeta is expanding the ongoing Phase IIb study of its second-generation insulin sensitizer. An insulin sensitizer with a better safety profile than first-generation drugs like Actos may provide a backbone therapy for NASH, the company believes.

Intercept Increases Chance Of Success In NASH Without Significant Delay

Ocaliva could now qualify for accelerated approval in NASH by meeting either of two Phase III co-primary endpoints, whereas the trial initially was designed for success on both measures.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098236

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel